CA3185618A1 - Modified semaphorin 3a, compositions comprising the same and uses thereof - Google Patents

Modified semaphorin 3a, compositions comprising the same and uses thereof

Info

Publication number
CA3185618A1
CA3185618A1 CA3185618A CA3185618A CA3185618A1 CA 3185618 A1 CA3185618 A1 CA 3185618A1 CA 3185618 A CA3185618 A CA 3185618A CA 3185618 A CA3185618 A CA 3185618A CA 3185618 A1 CA3185618 A1 CA 3185618A1
Authority
CA
Canada
Prior art keywords
sema3a
modified
polypeptide
semaphorin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3185618A
Other languages
English (en)
French (fr)
Inventor
Zahava Vadasz
Elias TOUBI
Nasren EIZA
Adi SABAG
Gera Neufeld
Ofra Kessler
E. Yvonne JONES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
Medical Research & Development Fund for Health Services Bnai Zion Medical Center
Technion Research and Development Foundation Ltd
Original Assignee
University of Oxford
Medical Research & Development Fund for Health Services Bnai Zion Medical Center
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oxford, Medical Research & Development Fund for Health Services Bnai Zion Medical Center, Technion Research and Development Foundation Ltd filed Critical University of Oxford
Publication of CA3185618A1 publication Critical patent/CA3185618A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3185618A 2020-06-04 2021-06-03 Modified semaphorin 3a, compositions comprising the same and uses thereof Pending CA3185618A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034476P 2020-06-04 2020-06-04
US63/034,476 2020-06-04
PCT/IL2021/050660 WO2021245670A1 (en) 2020-06-04 2021-06-03 Modified semaphorin 3a, compositions comprising the same and uses thereof

Publications (1)

Publication Number Publication Date
CA3185618A1 true CA3185618A1 (en) 2021-12-09

Family

ID=78830160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3185618A Pending CA3185618A1 (en) 2020-06-04 2021-06-03 Modified semaphorin 3a, compositions comprising the same and uses thereof

Country Status (8)

Country Link
US (1) US20230272020A1 (https=)
EP (1) EP4161659A4 (https=)
JP (1) JP2023532415A (https=)
CN (1) CN115916351A (https=)
AU (1) AU2021284697A1 (https=)
CA (1) CA3185618A1 (https=)
IL (1) IL298678A (https=)
WO (1) WO2021245670A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947817B (zh) * 2023-02-22 2024-07-02 甘肃中肽生物科技有限公司 一种肿瘤相关多肽及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2014199364A1 (en) * 2013-06-13 2014-12-18 Bnai Zion Medical Center Semaphorin 3a for treatment and prognosis of systemic lupus erythematosus
RU2722832C2 (ru) * 2015-02-23 2020-06-04 Сигалл Терапьютикс Сас Неприродные семафорины класса 3 и их медицинское применение

Also Published As

Publication number Publication date
WO2021245670A1 (en) 2021-12-09
IL298678A (en) 2023-01-01
AU2021284697A1 (en) 2023-01-19
US20230272020A1 (en) 2023-08-31
CN115916351A (zh) 2023-04-04
EP4161659A4 (en) 2024-03-06
EP4161659A1 (en) 2023-04-12
JP2023532415A (ja) 2023-07-28

Similar Documents

Publication Publication Date Title
KR102302392B1 (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
CN106659757A (zh) 白介素2的超级激动剂、部分激动剂和拮抗剂
JP2003531918A (ja) 抗炎症化合物及びその利用
WO2001019999A1 (en) A GENE ENCODING A NOVEL THREONYL-tRNA SYNTHETASE, ITS USES AND THE PREPARING METHODS
EP4310188A1 (en) Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
CN114302743B (zh) 用于治疗关节炎的hla-dr/cii肽复合体
CN102030822A (zh) 人类新细胞因子VSTM1-v2及其应用
US20230272020A1 (en) Modified semaphorin 3a, compositions comprising the same and uses thereof
US20050074756A1 (en) FALP proteins
KR20240128579A (ko) Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물
JP2001511645A (ja) ヒトＣ５ａ様受容体
US9943567B2 (en) Method for treating arthritis using IK factor or nucleic acid encoding IK factor
CN120019146A (zh) 通用t细胞和组合物及它们的使用方法
EP2706113B1 (en) Synthetic peptide capable of inducing expression of type-2 tnf receptor and use thereof
EP2032601B1 (en) Peptides regulating the surface expression of the t cell receptor
JP2001509015A (ja) ヒト塩素イオンチャネルタンパク質（ｈｃｃｐ）
US20010025098A1 (en) Human membrane-spanning proteins
US6908765B1 (en) Polypeptide—human SR splicing factor 52 and a polynucleotide encoding the same
HK40103877A (en) Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
HK40063235B (zh) 用於治疗关节炎的hla-dr/cii肽复合体
HK40126591A (zh) 通用t细胞和组合物及它们的使用方法
HK40063235A (en) Hla-dr/cii peptide complexes for treating arthritis
HK40064159B (zh) Mhc ii/cii肽复合体的产生
US20030148285A1 (en) Mammalian SIMP protein, gene sequence and uses thereof in cancer therapy
US20030118600A1 (en) Transfer compounds, production and use thereof

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251118

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204